<DOC>
	<DOCNO>NCT01369511</DOCNO>
	<brief_summary>The primary objective study test hypothesis appendicular lean body mass ( aLBM ) increase 12 week LY2495655 treatment versus placebo old participant undergo elective total hip arthroplasty ( eTHA ) .</brief_summary>
	<brief_title>A Study LY2495655 Older Participants Undergoing Elective Total Hip Replacement</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Males female partner childbearing potential use contraception treatment period trial 15 week last dose investigational product Females nonchild bear potential Elective total hip arthroplasty ( eTHA ) schedule Have body mass index &lt; 40 kilogram per square meter ( kg/ mÂ² ) weight &lt; 136.4 kg Can climb least 6 stair without hold handrail ( without human assistance ) , accord participant screening Can stand chair walk 10 meter without human assistance Take least 12 second perform Timed Up Go ( TUG ) test screen Another inpatient surgical procedure plan 6 month follow randomization Lower extremity amputation Lower limb fracture within 6 month prior screen major low limb surgery within 3 month prior randomization Simultaneous bilateral eTHA The planned surgical procedure preclude weight bear least 4 week postoperatively ( instance , planned procedure involve extensive bone grafting ) . `` Partial weight bearing '' `` weight bearing tolerate '' acceptable , `` non weightbearing , '' `` touch weight bearing , '' `` feather weight bearing '' exclusive Underlying muscle disease ( example , polymyositis muscular dystrophy ) history muscle disease ageassociated muscle waste disuse atrophy Recent neurologic injury ( &lt; 6 month prior randomization ) stroke spinal cord injury , unstable neurologic disorder likely confound physical performance test course study ( unstable Parkinson disease hemiplegia ) History positive test human immunodeficiency virus ( HIV ) Current use previous use drug know influence muscle mass performance within 6 month prior randomization ( include anabolic steroid , replacement therapy gonadal deficiency , antiandrogens , luteinizing hormonereleasing hormone [ LHRH ] agonist antagonist , growth hormone , InsulinLike Growth Factor 1 [ IGF1 ] , creatinine supplement ) , systemic corticosteroid use least 3 month ( last year ) prior randomization daily dose great equal 10 milligram ( mg ) prednisone equivalent Severe Vitamin D deficiency define 25hydroxyvitamin D level &lt; 9.2 nanogram per milliliter ( ng/mL ) &lt; 23 nanomole per milliliter ( nmol/mL ) screen History malignant neoplasm 5 year prior screen , exception superficial basal cell carcinoma squamous cell carcinoma skin definitively treat . Participants carcinoma situ uterine cervix treat definitively 1 year prior screening may enter study History follow condition within 90 day screen : Unstable angina , myocardial infarction , coronary artery bypass graft surgery , percutaneous coronary intervention ( eg , angioplasty stent placement ) Any current supraventricular arrhythmia uncontrolled ventricular response ( mean heart rate &gt; 100 beat per minute [ bpm ] ) rest despite medical device therapy , history spontaneous induce sustained ventricular tachycardia ( heart rate &gt; 100 bpm 30 second ) despite medical device therapy , history resuscitate cardiac arrest presence automatic internal cardioverterdefibrillator Any history congestive heart failure within 6 month screen Systolic blood pressure &gt; 160 &lt; 90 millimeter mercury ( mm Hg ) diastolic blood pressure &gt; 100 &lt; 50 mm Hg screening , malignant hypertension An abnormality locally read 12lead electrocardiogram ( ECG ) opinion investigator increase risk participate study Have either follow : Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2 time upper limit normal ( ULN ) , alkaline phosphatase &gt; 1.5 time ULN , total bilirubin &gt; 1.5 time ULN . Known history presence severe acute chronic liver disease History significant renal insufficiency , define receive renal dialysis estimate creatinine clearance &lt; 30 milliliter per minute ( mL/minute ) screen Current evidence recent history significant psychiatric disease dementia/Alzheimer 's disease , schizophrenia , bipolar disorder Are currently enrol , discontinue within last 30 day ( 5 half life whichever longer ) clinical trial involve investigational drug offlabel use drug , concurrently enrol type medical research judge scientifically medically compatible study Regularly use know drug abuse and/or show positive finding urinary drug screening ( physician prescribe narcotic allow ) Have positive fecal occult blood ( FOB ) test screen participant provide stool sample FOB test prior randomization Have uncontrolled diabetes mellitus Have ocular trauma , opthalmologic surgery , eye laser treatment within 6 month prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Disuse Atrophy</keyword>
	<keyword>Muscle</keyword>
	<keyword>Strength</keyword>
	<keyword>Arthroplasty</keyword>
	<keyword>Hip</keyword>
	<keyword>Joint Replacement</keyword>
</DOC>